Ken Griffin
ABCL icon

Ken Griffin’s AbCellera Biologics ABCL Stock Holding History

Ken Griffin’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.75M Sell
1,361,105
-473,403
-26% -$1.7M ﹤0.01% 4428
2025
Q4 		$6.27M Buy
1,834,508
+825,893
+82% +$3.69M ﹤0.01% 3939
2025
Q3 		$5.07M Sell
1,008,615
-1,881,145
-65% -$8.29M ﹤0.01% 4340
2025
Q2 		$9.91M Buy
2,889,760
+1,075,286
+59% +$2.68M ﹤0.01% 3033
2025
Q1 		$4.05M Buy
1,814,474
+1,217,223
+204% +$3.49M ﹤0.01% 4238
2024
Q4 		$1.75M Sell
597,251
-902,389
-60% -$2.51M ﹤0.01% 5911
2024
Q3 		$3.9M Buy
1,499,640
+26,430
+2% +$73.2K ﹤0.01% 4350
2024
Q2 		$4.36M Buy
1,473,210
+708,377
+93% +$2.68M ﹤0.01% 3963
2024
Q1 		$3.46M Buy
764,833
+186,527
+32% +$952K ﹤0.01% 4555
2023
Q4 		$3.3M Sell
578,306
-171,425
-23% -$794K ﹤0.01% 4490
2023
Q3 		$3.45M Sell
749,731
-1,444,039
-66% -$8.78M ﹤0.01% 4247
2023
Q2 		$14.2M Buy
2,193,770
+719,890
+49% +$4.91M ﹤0.01% 2248
2023
Q1 		$11.1M Buy
1,473,880
+8,884
+0.6% +$80.7K ﹤0.01% 2673
2022
Q4 		$14.8M Buy
1,464,996
+968,448
+195% +$11.2M ﹤0.01% 2310
2022
Q3 		$4.91M Buy
496,548
+329,348
+197% +$3.61M ﹤0.01% 3907
2022
Q2 		$1.78M Sell
167,200
-1,942
-1% -$16.4K ﹤0.01% 5787
2022
Q1 		$1.65M Sell
169,142
-248,948
-60% -$2.36M ﹤0.01% 6523
2021
Q4 		$5.98M Buy
418,090
+57,471
+16% +$872K ﹤0.01% 3989
2021
Q3 		$7.23M Sell
360,619
-42,990
-11% -$760K ﹤0.01% 3633
2021
Q2 		$8.88M Buy
403,609
+263,034
+187% +$7.25M ﹤0.01% 3276
2021
Q1 		$4.77M Sell
140,575
-291,782
-67% -$11.6M ﹤0.01% 4358
2020
Q4 		$17.4M Buy
+432,357
New +$19.8M ﹤0.01% 1953

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ken Griffin's ABCL Position: Q1 2026 in Review

Ken Griffin reduced its AbCellera Biologics (ABCL) stake by 26% in Q1 2026, selling an estimated $1.7M and leaving 1,361,105 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #4428.

Ken Griffin first reported a position in ABCL in Q4 2020 and has held it in 22 quarters since. The position peaked at $17.4M in Q4 2020. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Ken Griffin held 1,361,105 shares of AbCellera Biologics worth $4.75M as of Q1 2026.
  • Ken Griffin sold 473,403 AbCellera Biologics shares in Q1 2026, an estimated $1.7M.
  • AbCellera Biologics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #4428 holding.
  • Ken Griffin first reported a position in AbCellera Biologics in Q4 2020 and has held it in 22 quarters since.
  • Ken Griffin's AbCellera Biologics position peaked at $17.4M in Q4 2020.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.